A-Root Appoints Author Hwang Sok-yong as Standing Advisor to Expand Mecenat Activities

[Asia Economy Reporter Hyunseok Yoo] Aroot, a company listed on KOSDAQ, announced on the 21st that it has appointed Hwang Sok-yong, a representative writer of Korean literature, as its standing advisor. Marking this advisory appointment, Aroot plans to engage in patronage activities to promote Korean literature and globalize K-literature.

Hwang Sok-yong, who recently appeared to the public through a broadcast program in May, won the Sasanggye New Writer's Literary Award in 1962 for "Ipseok Bugeun." He officially embarked on his writing career in 1970 when his short story "Top" was selected in the Chosun Ilbo New Year's Literary Contest. Since then, he has published masterpieces that have left a mark in the history of Korean literature, including "The Chronicle of Han," "The Road to Sampo," "The Shadow of Arms," and "Jang Gil-san."

Hwang Sok-yong is recognized as a leading Korean novelist, renowned not only domestically but also internationally, with his works translated and published in 32 countries worldwide.

An Aroot official stated, "We are honored to have the era-defining writer Hwang Sok-yong as an advisor to our company," adding, "Together with Advisor Hwang, Aroot plans to promote Korean literature and widely publicize K-literature globally, as well as support various artistic activities."

Accepting the standing advisor position at Aroot, Hwang Sok-yong said, "I am grateful that Aroot, a domestic listed company, is taking the lead in supporting the global promotion of Korean literature," and added, "Just as Korean films and popular music are loved worldwide, I believe Korean literature will also receive love from people around the world."

Aroot, a company specializing in industrial printers, has a sales network of over 200 locations in more than 70 countries worldwide, with overseas sales accounting for 80% of its revenue, making it a strong small and medium enterprise. It also has 'Gionics,' a UPS specialist company, as its subsidiary. Recently, to secure future growth engines, the company invested in 'Virocure,' which is developing cancer treatments using oncolytic viruses.

This content was produced with the assistance of AI translation services.